EQL PHARMA AB (7JK) - Total Liabilities
Based on the latest financial reports, EQL PHARMA AB (7JK) has total liabilities worth €543.76 Million EUR (≈ $635.71 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
EQL PHARMA AB - Total Liabilities Trend (2022–2025)
This chart illustrates how EQL PHARMA AB's total liabilities have evolved over time, based on quarterly financial data. See EQL PHARMA AB (7JK) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
EQL PHARMA AB Competitors by Total Liabilities
The table below lists competitors of EQL PHARMA AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
5E Advanced Materials Inc
AU:5EA
|
Australia | AU$5.10 Million |
|
Identiv Inc
NASDAQ:INVE
|
USA | $7.36 Million |
|
Grupe S.A.B. de C.V
MX:CIDMEGA
|
Mexico | MX$4.06 Billion |
|
GAM Holding AG
SW:GAM
|
Switzerland | CHF93.20 Million |
|
Chuwa Wool Industry Co Taiwan Ltd
TW:1439
|
Taiwan | NT$2.55 Billion |
|
Mobile Infrastructure Corporation
NASDAQ:BEEP
|
USA | $223.42 Million |
|
Ekinops SA
PA:EKI
|
France | €88.40 Million |
|
Eyenovia Inc
NASDAQ:EYEN
|
USA | $15.70 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down EQL PHARMA AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EQL PHARMA AB stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how EQL PHARMA AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for EQL PHARMA AB (2022–2025)
The table below shows the annual total liabilities of EQL PHARMA AB from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | €587.79 Million ≈ $687.19 Million |
+199.84% |
| 2024-03-31 | €196.03 Million ≈ $229.18 Million |
+49.71% |
| 2023-03-31 | €130.94 Million ≈ $153.09 Million |
+14.60% |
| 2022-03-31 | €114.26 Million ≈ $133.58 Million |
-- |
About EQL PHARMA AB
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.